Approval · Notice of Compliance 33298 · 2024
AG-DUTASTERIDE: Notice of Compliance 33298
Issued May 24, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33298
- Date
- May 24, 2024
- Company
- Angita Pharma Inc.Boucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AG-DUTASTERIDE | 02485672 | Marketed |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP